Literature DB >> 15700032

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer.

K Canna1, P A McArdle, D C McMillan, A-M McNicol, G W Smith, R F McKee, C S McArdle.   

Abstract

There is increasing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of common solid tumours. The aim of the present study was to examine the relationship between tumour T-lymphocyte subset infiltration, the systemic inflammatory response and cancer-specific survival in patients with colorectal cancer. In all, 147 patients undergoing potentially curative resection for colorectal cancer were studied. Circulating concentrations of C-reactive protein were measured prior to surgery. CD4+ and CD8+ T-lymphocyte infiltration of the tumour was assessed using immunohistochemistry and a point counting technique. When patients were grouped according to the percentage tumour volume of CD4+ T-lymphocytes, there was no difference in terms of age, sex, tumour site, stage and tumour characteristics. However, there was an inverse relationship between percentage tumour CD4+ T-lymphocytes and C-reactive protein (P<0.01). On univariate analysis, both C-reactive protein concentrations (P<0.001) and percentage tumour volume of CD4+ (P<0.05) T-lymphocytes were associated with cancer-specific survival. The results of the present study show that low tumour CD4+ T-lymphocyte infiltration is associated with elevated C-reactive protein concentrations and both predict poor cancer-specific survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700032      PMCID: PMC2361875          DOI: 10.1038/sj.bjc.6602419

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


It has long been recognised that disease progression in cancer patients is not solely determined by the characteristics of the tumour but also by the host response. Indeed, there is increasing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of common solid tumours (O'Byrne and Dalgleish, 2001; Vakkila and Lotze, 2004). In patients with colorectal cancer, there is good evidence that, on simple staining of tumour sections, the presence of a pronounced lymphocytic infiltration within the tumour is associated with improved survival (Jass ; Ropponen ; Nielsen ). More recently, the ability to identify lymphocyte subsets by immunohistochemistry has led to renewed interest in the relationship between the tumour inflammatory infiltrate and outcome. Indeed, increased infiltration of the tumour by CD8+ (Naito ) and CD4+ T-lymphocytes (Ali ) has been shown to be associated with increased survival in patients with colorectal cancer. There is also increasing evidence that the presence of a systemic inflammatory response, as evidenced by elevated circulating concentrations of C-reactive protein, is associated with early recurrence and poorer survival in patients undergoing potentially curative resection for colorectal cancer (McMillan , 2003; Nielsen ). To date, the inter-relationships between the local and systemic inflammatory responses and outcome does not appear to have been examined in patients with colorectal cancer. The aim of the present study was therefore to examine the relationship between tumour T-lymphocyte subset infiltration, circulating concentrations of C-reactive protein and cancer-specific survival in patients who had undergone potentially curative resection for colorectal cancer.

PATIENTS AND METHODS

Patients

Patients with histologically proven colorectal cancer who, on the basis of preoperative imaging and the surgeons' assessment at operation, were considered to have undergone potentially curative resection for Dukes' B and C colorectal cancer between January 1997 and August 2001 in a single surgical unit at Glasgow Royal Infirmary were included in the study. A blood sample was taken prior to surgery for the measurement of C-reactive protein. The tumours were staged using conventional Dukes' classification (Dukes and Bussey, 1958). All patients were followed up at a specialist colorectal cancer clinic. C-reactive protein concentrations were measured by a fluorescence polarisation immunoassay and using an Abbott TDXTM analyser and Abbott reagents (Abbott Laboratories, Abbott Park, IL, USA). The limit of detection of the assay is a CRP concentration lower than 5 mg l−1. The coefficient of variation, over the range of measurement, was less than 5%, as established by routine quality control procedures. Based on previous work, a C-reactive protein concentration of greater than 10 mg l−1 was considered to indicate the presence of a systemic inflammatory response (O'Gorman ). The study was approved by the local ethics committee.

Immunohistochemistry

Blocks from the primary tumour were fixed in 10% buffered formalin and embedded in paraffin wax. One representative block of tumour was selected for each patient. Sections (4 μm) were cut and mounted on slides coated with aminopropyltriethoxysilane. Sections were then immunostained using the peroxidase-based Envision (Dako, Cambridgeshire, UK) technique as described previously (Bromwich ). The primary antibody for CD4 was mouse monoclonal (Vector, Peterborough, UK) and that for CD8 was mouse monoclonal (Dako, Cambridgeshire, UK).

Morphometry

Quantitative analysis of the lymphoid infiltrate was performed using point counting (Anderson and Dunnill, 1965) with a random sampling technique. With this method, the volume occupied by any given component (volume density) is expressed as a percentage of the total volume of the tissue. A 100-point ocular grid was used at 400 × magnification and 30 fields were counted per case for CD4+ and CD8+ immunopositive cells. Only fields within the tumour (including cancer cell nests and surrounding tissue stroma) were counted. Any normal tissue on the slide was excluded from the analysis. This final method was designed on the basis of a pilot study, which demonstrated that the volume density of CD4+ and CD8+ of two observers reached a plateau after 25–30 fields. This pilot study also demonstrated that CD4+ and CD8+ counts were equivalent to the CD3+ counts (unpublished data). The observers (Canna and McArdle) were blinded to the clinical outcome of the patient.

Statistics

Data are presented as median and range. Where appropriate, comparison of patient groups of patients was carried out using contingency table analysis (χ2) and the Kruskal–Wallis test for analysis of variance. For the purpose of analysis, T-lymphocyte subsets were grouped by tertiles as described previously (Nielsen ). Survival analysis was performed using the Cox proportional-hazard model. Deaths up to 31st March 2004 have been included in the analysis. Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).

RESULTS

The baseline clinicopathological characteristics of the patients (n=147) who underwent potentially curative resection for colorectal cancer are shown in Table 1. The majority were over the age of 65years and had Dukes' stage B tumours. In all, 53 (36%) patients had an elevated C-reactive protein concentration prior to surgery.
Table 1

Clinicopathological characteristics in patients undergoing potentially curative resection for colorectal cancer

  Patients (n=147)
Age group (years) (<65/65–74/⩾75)46/44/57
Sex (male/female)78/69
Site (colon/rectum)105/42
Dukes' stage (B/C)91/56
C-reactive protein (⩽10/>10 mg l−1)94/53
 
Tumour characteristics
 Diameter (mm)40 (10–130)
 Ulceration (no/yes)72/75
 Differentiation (well/moderate/poor)18/116/13
 Lymphatic invasion (negative/positive)124/22
 Venous invasion (negative/positive)118/28
 
% Tumour volume
 CD4+ T-lymphocytes0.90 (0.03–3.57)
 CD8+ T-lymphocytes1.13 (0.23–6.30)
 CD4+ plus CD8+ T-lymphocytes2.17 (0.50–8.27)
 
Adjuvant therapy (no/yes)116/31
Alive/dead92/55
 Cancer-specific/intercurrent disease39/16
Patients grouped according to tertiles of the percentage tumour volume of CD4+ T-lymphocytes are shown in Table 2. The tertiles were similar in terms of age, sex, tumour site, stage and tumour characteristics. There was an inverse relationship between percentage tumour CD4+ T-lymphocytes and C-reactive protein (rs=−0.245, P=0.003, Figure 1). However, there was no relationship between percentage tumour CD8+ T-lymphocytes and C-reactive protein (rs=−0.091, P=0.273). There was a positive relationship between percentage tumour CD4+ and CD8+ T-lymphocytes (rs=0.440, P<0.001).
Table 2

Relationship between increasing percentage volume of CD4+ T-lymphocytes and tumour characteristics in patients undergoing potentially curative resection for colorectal cancer

  Percentage volume of CD4+ T-lymphocytes
  Tertile (n=49) Tertile (n=49) Tertile (n=49) P-value
Age group (years) (<65/65–74/⩾75)12/13/2419/11/1915/20/140.122
Sex (male/female)22/2724/2532/170.101
Site (colon/rectum)35/1436/1334/150.905
Dukes' stage (B/C)30/1933/1628/210.578
C-reactive protein (⩽10/>10 mg l−1)22/2732/1739/100.002
 
Tumour characteristics
 Diameter (tertiles)15/17/1716/12/2118/20/110.250
 Ulceration (no/yes)21/2822/2729/200.212
 Differentiation (well/moderate/poor)6/38/57/37/55/41/30.883
 Lymphatic invasion (negative/positive)40/843/641/80.794
 Venous invasion (negative/positive)38/1042/738/110.554
Figure 1

Relationship between percentage tumour CD4+ T-lymphocyte infiltration and preoperative C-reactive protein in patients undergoing potentially curative resection for colorectal cancer.

The minimum follow-up was 30 months; the median follow-up of the survivors was 62 months. During the course of the study, 55 patients died, 39 patients of their cancer and 16 of intercurrent disease. On univariate analysis, increased age (P<0.001), sex (P=0.052), Dukes' stage (P<0.001) and venous invasion (P=0.002) were associated with poorer cancer-specific survival. A decreased percentage tumour volume of CD4+ T-lymphocytes (P=0.025, Figure 2) and an elevated C-reactive protein (P<0.001, Figure 3) were also associated with poorer cancer-specific survival. However, the relationship between percentage tumour volume of CD8+ T-lymphocytes and cancer-specific survival failed to reach statistical significance (P=0.074).
Figure 2

Relationship between tumour CD4+ T-lymphocyte infiltration (tertiles decreasing from top to bottom) and cancer-specific survival in patients undergoing potentially curative resection for colorectal cancer.

Figure 3

Relationship between preoperative C-reactive protein (⩽10/>10 mg l−1 from top to bottom) and cancer-specific survival in patients undergoing potentially curative resection for colorectal cancer.

On multivariate analysis, only age (HR 2.05, 95% CI 1.30–3.23, P=0.002), stage (HR 4.39, 95% CI 2.14–9.00, P<0.001) and C-reactive protein (HR 4.66, 95% CI 2.20–9.89, P<0.001) retained independent significance.

DISCUSSION

In the present study, a poor tumour CD4+ T-lymphocyte infiltrate was associated with an elevated circulating C-reactive protein concentration in patients undergoing potentially curative resection for colorectal cancer. Furthermore, both CD4+ T-lymphocytes and C-reactive protein were associated with a poor outcome. Therefore, the results of the present study indicate that both local and systemic inflammatory responses are linked and predict outcome independent of tumour stage. These results appear to be consistent with previous work by Naito , who showed that tumour CD8+ T-lymphocyte infiltrate had prognostic value in patients with colorectal cancer. However, they did not assess the tumour CD4+ T-lymphocyte infiltrate and used a less extensive sampling method. Furthermore, they included patients with Dukes' A tumours who were unlikely to progress and patients with Dukes' D tumours who had already progressed (Naito ). In the present study, tumour T-lymphocyte subset density was assessed using extensive sampling and a point counting technique. This approach provided an objective assessment of lymphocytic infiltration and circumvents the problem of variation in distribution of lymphocytes within an individual tumour. The present study was also confined to patients with Dukes' B and C tumours. It was of interest that C-reactive protein (a systemic inflammatory response) was superior to tumour T-lymphocytic infiltration (a local inflammatory response) in predicting cancer specific survival. One possible explanation is that C-reactive protein can be measured with greater accuracy and precision than tumour T-lymphocytic infiltration. Alternatively, the systemic inflammatory response may be more important in determining survival in these patients. The relationship between tumour CD4+ T-lymphocytic infiltration and cancer-specific survival is the opposite of that previously reported for both renal and prostate cancer (Bromwich ; McArdle ). The reasons for this are as yet unclear. However, given that tumour lymphocytic infiltration parallels that of other inflammatory cells (Nielsen ; Lin and Pollard, 2004) and that an elevated C-reactive protein is associated with poor outcome in all three tumours (Lewenhaupt ; Blay ; McMillan ), it appears likely that the source of interleukin-6, the primary stimulus for the production of C-reactive protein, (Gabay and Kushner, 1999), differs in different tumours. It is of interest therefore that McArdle have recently reported that the relationship between interleukin-6 and C-reactive protein was similar in benign prostatic hyperplasia and prostate cancer, and that there was no relationship between interleukin-6 and PSA concentrations. This would suggest that, in prostate cancer at least, interleukin-6 is produced by the inflammatory cells. In colorectal cancer, it has been reported that interleukin-6 concentrations increase with tumour stage and correlate with CEA concentrations. This might therefore suggest that interleukin-6 is produced by the tumour cells (Kinoshita ; Belluco ; Miki ). If this were to prove to be the case, it would have important implications for the treatment of the systemic inflammatory response in patients with different tumours. In the present study, we attempted to assess interleukin-6 within the tumour using different methods of antigen retrieval and staining and the use of negative and positive controls. However, we were unable to reliably identify regions of IL-6 expression in the colorectal tumours due to deep background staining, which precluded accurate scoring of IL-6-positive cells in the tumour tissue. In summary, the results of the present study show that, in patients undergoing curative resection for colorectal cancer, low tumour CD4+ T-lymphocyte infiltration is associated with elevated C-reactive protein concentrations. Furthermore, both a low tumour CD4+ T-lymphocyte infiltration and an elevated C-reactive protein predict poor cancer-specific survival.
  22 in total

Review 1.  Inflammation and necrosis promote tumour growth.

Authors:  Jukka Vakkila; Michael T Lotze
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

2.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  A new prognostic classification of rectal cancer.

Authors:  J R Jass; S B Love; J M Northover
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

4.  Tumour markers as prognostic aids in prostatic carcinoma.

Authors:  A Lewenhaupt; P Ekman; P Eneroth; B Nilsson
Journal:  Br J Urol       Date:  1990-08

5.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

6.  C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma.

Authors:  Chikao Miki; Naomi Konishi; Eiki Ojima; Tsuyoshi Hatada; Yasuhiro Inoue; Masato Kusunoki
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

7.  Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer.

Authors:  A A Ali; D C McMillan; I I Matalka; A M McNicol; C S McArdle
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

Review 8.  Chronic immune activation and inflammation as the cause of malignancy.

Authors:  K J O'Byrne; A G Dalgleish
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

9.  The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer.

Authors:  P A McArdle; K Canna; D C McMillan; A-M McNicol; R Campbell; M A Underwood
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

Review 10.  Role of infiltrated leucocytes in tumour growth and spread.

Authors:  E Y Lin; J W Pollard
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

View more
  81 in total

1.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

Review 2.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

3.  Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Authors:  Lutfiye Demir; Seyran Yigit; Hulya Ellidokuz; Cigdem Erten; Isil Somali; Yuksel Kucukzeybek; Ahmet Alacacioglu; Suna Cokmert; Alper Can; Murat Akyol; Ahmet Dirican; Vedat Bayoglu; Aysegul Akder Sari; Mustafa Oktay Tarhan
Journal:  Clin Exp Metastasis       Date:  2013-07-09       Impact factor: 5.150

4.  Usefulness of Inflammation-Based Prognostic Score in Patients Undergoing Lung Metastasectomy for Colorectal Carcinoma.

Authors:  Satoru Kobayashi; Yoko Karube; Morimichi Nishihira; Takashi Inoue; Osamu Araki; Tetsu Sado; Masayuki Chida
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

5.  The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer.

Authors:  Tsuyoshi Ozawa; Soichiro Ishihara; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2015-06-07       Impact factor: 2.571

6.  Systemic inflammatory response associated with distant metastasis of T1 or T2 colorectal cancer.

Authors:  Mitsuru Ishizuka; Hitoshi Nagata; Kazutoshi Takagi; Keiichi Kubota
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

7.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yoshihiro Shirai; Takashi Horiuchi; Ryota Iwase; Yuki Fujiwara; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

8.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

9.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

Authors:  D Gomez; S Farid; H Z Malik; A L Young; G J Toogood; J P A Lodge; K R Prasad
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

10.  Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma.

Authors:  E J Clark; S Connor; M A Taylor; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.